🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

and what is a high resolution typing? (5/7)

Another addition for treating #chronicGVHD ! U.S. FDA approves axatilimab-csfr #Niktimvo. Very promising agent from pathophysiological point with low toxicity profile! #Ruxolitinib #Belumosudil #Axatilimab fda.gov/drugs/resource… #BMT

Is HLA mismatching nullified by PTCy-based GVHD prophylaxis in MMUD Transplantation? This new paper from EBMT's CTIWP, which just came out in JCO, challenges the notion that PTCy completely overcomes the deleterious impact of HLA mismatching ascopubs.org/doi/10.1200/JC…

#Chandrapur- From being in Naxal affected Garchiroli region to becoming home to Centre for research management and control of hemoglobinopathies #CRMCH -city has come a long way Hosting top meeting on sickle cell disease ICMR & NIH Chief guest-Dr Mohan Narla ASH president

Orca Bio will present results from the pivotal Phase 3 Precision-T study of its investigational Orca-T in people with hematological malignancies at #EBMT25. The study met its primary endpoint of an improvement in survival free of moderate-to-severe cGvHD with Orca-T vs.

Insights into Advanced Surgical Techniques for Neuroblastoma my.clevelandclinic.org/podcasts/cance… via @clevelandclinic Dale Shepard MD, PhD

📝 A new study published in @BloodJournal found that rovadicitinib treatment led to a best overall response of 86.4%, with no dose-limiting toxicities. More news: gvhdhub.com #GvHD #MedNews #MedEd

link.springer.com/article/10.100… Risk adapted strategy in #Wilms #tumor works. NWTS for early staging avoiding over treatment with Adriamycin. SIOP for advanced stages avoiding tumor spill and consequent radiation. 5 year OS >90% for the entire cohort.

Great work! IKAROSlow cells exhibit higher resistance to CD19, CD22-targeted therapies. Will this be applicable to #Blina also?

Intrathecal MTX Prophylaxis 💉🧠 in DLBCL: No Impact on Parenchymal CNS Relapse •Key Point: Most CNS relapses in DLBCL are parenchymal, not leptomeningeal •Implication: IT chemotherapy alone (e.g., MTX) doesn’t prevent CNS relapse •Multiple trials confirm: •RICOVER-60: 6.9%

Targeted #Busulfan based #conditioning equivalent EFS/GRFS to #TBI based regimens in children with #AcuteLymphoblasticLeukemia #FORUM subgroup analysis #EBMT25. Children <2 benefited the most. Optimal #AUC (73.3-98 mg.h/L) without higher toxicity.(Same as 'Bartelink' window)

Checkpoint inhibitors checkmate solid tumors having genetic Mismatch repair deficiency Nonoperative Management of Mismatch Repair–Deficient Tumors nejm.org/doi/full/10.10…

At many large institutions, it’s now common for nurses to have the authority to question, and sometimes override, physician decisions. This isn’t inherently a bad thing. Patient safety should always come first, and questioning orders when there's a genuine concern should be

Out now, our bit for Low Dose ImmunoRx #LoDoNiv in relapse/refractory Ped Classic Hodgkin cHL #PHLDMG Tata Memorial Hospital Fixed #LoDoNiv 40mg + Benda -> 88%CR Will now be prospective multicenter INPHOG study PHO INDIA Excellent work Shyam Chetan Dhamne & rising star Aditya Narayan

🧬✨ ATRA Goes Beyond APL! 🔬💊 All-trans retinoic acid (ATRA), the vitamin A derivative that cured APL by reactivating differentiation in leukemic blasts, is now stepping into non-APL AML 🧠🔥 🧱 In a new twist, ATRA doesn’t target blasts directly—but instead acts on the bone

29% higher risk of B-cell #Acuteleukemia before 5 years of age in a child(mainly boys 41% higher risk) born through PLANNED C-SECTION!—A Swedish population‐based study. #VaginalDelivery not only prevents Allergies, Asthma or Diabetes but also #Leukemia! onlinelibrary.wiley.com/doi/10.1002/ij…

A monumental Review ! IKZF-associated inborn errors of immunity rupress.org/jhi/article/1/…

Bone Marrow Transplantation for Sickle Cell Disease: A Study of Parents' Decisions: New England Journal of Medicine: Vol 325, No 19 1991 NEJM study found that 54% of parents of kids with sickle cell disease were willing to accept a 15% mortality risk from bone marrow